Merck, Lycera broaden partnership on autoimmune disease drugs

Merck & Co. expanded a collaboration with Lycera to develop and market small-molecule drugs against autoimmune diseases. The deal entitles Lycera to an undisclosed upfront fee and research support plus more than $300 million in possible milestone fees, plus royalties. Merck will handle clinical development, and will get the global rights to marketing.

View Full Article in:

Genetic Engineering & Biotechnology News · Crain's Detroit Business (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ